Boston Scientific
The Legacy Study is a robust multicenter study confirming TheraSphere™ as a neoadjuvant or standalone therapy in treating HCC.
Click here to view the presentation which provides background on the use of TheraSphere™ Y-90 glass microspheres to treat HCC, discusses results of the LEGACY study and recently published studies using Y-90 glass microspheres.
Comments 0
Login to view comments.
Click here to Login
